%20(2).png){kind=logo}
GLP-1 drugs like Ozempic are reshaping consumer behavior beyond food by disrupting industries such as retail, casinos, airlines, and fitness, prompting brands to rethink engagement strategies.
Fierce Pharma Week unites top life science leaders in marketing, sales, medical affairs, PR & Communications, and commercialization to ignite innovation and drive strategy. Get ready to accelerate your brand's impact, power agile growth, and thrive in pharma’s fast-paced future.
Donald Trump's 2024 campaign and potential second term could reshape U.S. healthcare policy, including deregulation, cost transparency, and the rollback of Biden-era initiatives.
Chase Feiger outlines four essential strategies—ensuring regulatory compliance, fostering explainable AI, aligning with real-world life‑sciences use cases, and building strong cross-functional teams—to successfully implement AI in life-sciences organizations.
Senators are pushing to regulate or limit direct-to-consumer pharmaceutical advertising, raising concerns in the industry that such actions could threaten its $2 billion R&D investment model.
President Donald Trump signed on May 12 an executive order, the Most-Favored-Nation (MFN) prescription drug pricing policy, aimed to cut some U.S. medicine prices to match lower ones abroad.
The FDA's Elsa AI tool represents a pivotal step in integrating generative AI to streamline drug review processes and modernize regulatory practices.
The FDA's rollout of the AI tool "Elsa" was a predictable milestone in its broader, strategic shift toward generative AI-driven efficiencies in drug review processes, signaling the start of deeper transformative changes across regulatory operations.
The FDA's new generative AI tool, Elsa, is now accelerating clinical protocol reviews by summarizing data, identifying priorities, and streamlining workflows–marking a significant leap forward in regulatory review efficiency.
.svg)